<DOC>
	<DOC>NCT01256151</DOC>
	<brief_summary>To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.</brief_summary>
	<brief_title>Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Signed informed consent. Evidence or history of clinically significant abnormalities Positive drug screen, excessive alcohol and tobacco use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>sublingual</keyword>
	<keyword>alprazolam</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>